Pertti Jaakko Neuvonen

List of Publications by Year
in descending order

334	24,374	5268	11308
papers	citations	83 h-index	136 g-index

337	337	337	11247
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Lifetime antimicrobial use is associated with weight status in early adolescenceâ€"A registerâ€based cohort study. Pediatric Obesity, 2021, 16, e12727.	2.8	1
2	Itraconazole Increases Ibrutinib Exposure 10â€Fold and Reduces Interindividual Variationâ€"A Potentially Beneficial Drugâ€Drug Interaction. Clinical and Translational Science, 2020, 13, 345-351.	3.1	25
3	A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drugâ€"Drug Interactions. Clinical Pharmacokinetics, 2020, 59, 781-808.	3.5	42
4	Antimicrobial drug use in the first decade of life influences saliva microbiota diversity and composition. Microbiome, 2020, 8, 121.	11.1	18
5	CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel. Clinical Pharmacology and Therapeutics, 2019, 105, 448-457.	4.7	22
6	Sotalol, unlike the other betaâ€blockers, increases the QT_c interval and risk of torsades de pointes ventricular tachycardia in severe poisonings. Basic and Clinical Pharmacology and Toxicology, 2019, 125, 487-488.	2.5	0
7	Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. Drug Metabolism and Disposition, 2019, 47, 377-385.	3.3	15
8	Withdrawal from longâ€term use of zopiclone, zolpidem and temazepam may improve perceived sleep and quality of life in older adults with primary insomnia. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 330-340.	2.5	23
9	Response to â€œInteraction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test?â€. Clinical Pharmacology and Therapeutics, 2019, 105, 322-322.	4.7	1
10	Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. Clinical Pharmacology and Therapeutics, 2019, 105, 219-228.	4.7	51
11	Analgesic Plasma Concentrations of Oxycodone After Surgery for Breast Cancerâ€"Which Factors Matter?. Clinical Pharmacology and Therapeutics, 2018, 103, 653-662.	4.7	20
12	Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 341-345.	2.5	12
13	Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8â€Mediated Metabolism of Montelukast in Humans. Clinical Pharmacology and Therapeutics, 2018, 104, 495-504.	4.7	14
14	Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions^{â€‰}. Drug Metabolism and Disposition, 2018, 46, 141-150.	3.3	22
15	Semimechanistic Population Pharmacokinetic Model to Predict the Drugâ€"Drug Interaction Between Sâ€ketamine and Ticlopidine in Healthy Human Volunteers. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 687-697.	2.5	17
16	Voriconazole greatly increases the exposure to oral buprenorphine. European Journal of Clinical Pharmacology, 2018, 74, 1615-1622.	1.9	12
17	Long-term persistence of withdrawal of temazepam, zopiclone, and zolpidem in older adults: a 3-year follow-up study. BMC Geriatrics, 2018, 18, 142.	2.7	5
18	Stress-Dose Corticosteroid Versus Placebo in Neonatal Cardiac Operations: A Randomized Controlled Trial. Annals of Thoracic Surgery, 2017, 104, 1378-1385.	1.3	21

#	Article	IF	Citations
19	Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 83-95.	3.3	30
20	Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. Drug Metabolism and Disposition, 2016, 44, 1364-1371.	3.3	30
21	Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects. Pharmacology Research and Perspectives, 2016, 4, e00271.	2.4	9
22	High-Dose Methylprednisolone Has No Benefit Over Moderate Dose for the Correction of Tetralogy of Fallot. Annals of Thoracic Surgery, 2016, 102, 870-876.	1.3	13
23	Lipid Rescue â€“ Efficacy and Safety Still Unproven. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 345-348.	2.5	6
24	Postoperative oxycodone in breast cancer surgery: What factors associate with analgesic plasma concentrations?. Scandinavian Journal of Pain, 2016, 12, 118-119.	1.3	0
25	Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. European Journal of Clinical Pharmacology, 2016, 72, 1363-1371.	1.9	15
26	Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacological Reviews, 2016, 68, 168-241.	16.0	175
27	Effect of carboxylesterase 1 c.428Gâ€‰>â€‰A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. British Journal of Clinical Pharmacology, 2015, 80, 1131-1138.	2.4	35
28	Drugâ€Related Inadvertent Deaths in a University Hospital â€“ A Declining Trend. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 421-426.	2.5	22
29	SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. Pharmacogenetics and Genomics, 2015, 25, 382-387.	1.5	122
30	Effect of Timing and Route of Methylprednisolone Administration During Pediatric Cardiac Surgical Procedures. Annals of Thoracic Surgery, 2015, 99, 180-185.	1.3	30
31	Effect of grapefruit juice on the bioactivation of prasugrel. British Journal of Clinical Pharmacology, 2015, 80, 139-145.	2.4	13
32	Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. European Journal of Clinical Pharmacology, 2015, 71, 321-327.	1.9	30
33	Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. Clinical Pharmacology and Therapeutics, 2015, 97, 650-658.	4.7	70
34	The role of concentrationâ^'effect relationships in the QTcinterval prolongation: case sotalol. British Journal of Clinical Pharmacology, 2015, 79, 1040-1041.	2.4	1
35	Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate Simvastatin. Drug Metabolism and Disposition, 2015, 43, 1655-1660.	3.3	25
36	Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drugâ€“Drug Interactions. Clinical Pharmacology and Therapeutics, 2014, 96, 498-507.	4.7	124

#	Article	IF	Citations
37	Handgrip strength and balance in older adults following withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotics. BMC Geriatrics, 2014, 14, 121.	2.7	20
38	Paroxetine Markedly Increases Plasma Concentrations of Ophthalmic Timolol; CYP2D6 Inhibitors May Increase the Risk of Cardiovascular Adverse Effects of 0.5% Timolol Eye Drops. Drug Metabolism and Disposition, 2014, 42, 2068-2076.	3.3	9
39	Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial. British Journal of Clinical Pharmacology, 2014, 77, 975-985.	2.4	33
40	Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults. European Journal of Clinical Pharmacology, 2014, 70, 319-329.	1.9	32
41	Infections and possible vaccine-drug interactions. European Journal of Clinical Pharmacology, 2014, 70, 889-890.	1.9	1
42	Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel. Clinical Pharmacology and Therapeutics, 2014, 95, 307-313.	4.7	49
43	In Vitro Assessment of Time-Dependent Inhibitory Effects on CYP2C8 and CYP3A Activity by Fourteen Protein Kinase Inhibitors. Drug Metabolism and Disposition, 2014, 42, 1202-1209.	3.3	56
44	Rifampicin markedly decreases the exposure to oral and intravenous tramadol. European Journal of Clinical Pharmacology, 2013, 69, 1293-1301.	1.9	25
45	Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction. European Journal of Clinical Pharmacology, 2013, 69, 867-875.	1.9	15
46	Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification. In Silico Pharmacology, 2013, 1, 6.	3.3	41
47	Autoinhibition of CYP3A4 Leads to Important Role of CYP2C8 in Imatinib Metabolism: Variability in CYP2C8 Activity May Alter Plasma Concentrations and Response. Drug Metabolism and Disposition, 2013, 41, 50-59.	3.3	57
48	Methylprednisolone in Neonatal Cardiac Surgery: Reduced Inflammation Without Improved Clinical Outcome. Annals of Thoracic Surgery, 2013, 95, 2126-2132.	1.3	64
49	Intravenous Lipid Emulsion Entraps Amitriptyline into Plasma and Can Lower its Brain Concentration â€“ An Experimental Intoxication Study in Pigs. Basic and Clinical Pharmacology and Toxicology, 2013, 113, 193-200.	2.5	45
50	A Semiphysiological Population Pharmacokinetic Model for Dynamic Inhibition of Liver and Gut Wall Cytochrome P450Â3A by Voriconazole. Clinical Pharmacokinetics, 2013, 52, 763-781.	3.5	33
51	A Randomized Clinical Trial of Histamine 2 Receptor Antagonism in Treatment-Resistant Schizophrenia. Journal of Clinical Psychopharmacology, 2013, 33, 472-478.	1.4	52
52	Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. British Journal of Clinical Pharmacology, 2013, 75, 1488-1496.	2.4	32
53	SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren. Pharmacogenetics and Genomics, 2013, 23, 19-24.	1.5	36
54	Acetaminophen Improves Analgesia but Does Not Reduce Opioid Requirement After Major Spine Surgery in Children and Adolescents. Spine, 2012, 37, E1225-E1231.	2.0	80

#	Article	IF	Citations
55	Intravenous Lipid Emulsion Only Minimally Influences Bupivacaine and Mepivacaine Distribution in Plasma and Does Not Enhance Recovery from Intoxication in Pigs. Anesthesia and Analgesia, 2012, 114, 901-906.	2.2	30
56	Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends in Pharmacological Sciences, 2012, 33, 312-322.	8.7	85
57	Potent mechanismâ€based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. British Journal of Pharmacology, 2012, 165, 2787-2798.	5.4	74
58	St Johnâ€™s wort greatly decreases the plasma concentrations of oral Sâ€ketamine. Fundamental and Clinical Pharmacology, 2012, 26, 743-750.	1.9	31
59	Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in Humans. Clinical Pharmacology and Therapeutics, 2012, 92, 68-71.	4.7	64
60	Increased incidence of Merkel cell carcinoma among younger statin users. Cancer Epidemiology, 2012, 36, 421-424.	1.9	22
61	In vitro and in vivo entrapment of bupivacaine by lipid dispersions. Journal of Chromatography A, 2012, 1254, 125-131.	3.7	9
62	Statins and Hip Fracture Prevention â€“ A Population Based Cohort Study in Women. PLoS ONE, 2012, 7, e48095.	2.5	32
63	Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. European Journal of Clinical Pharmacology, 2012, 68, 681-688.	1.9	13
64	S-ketamine concentrations are greatly increased by grapefruit juice. European Journal of Clinical Pharmacology, 2012, 68, 979-986.	1.9	26
65	Re: Pergolizzi etÂal. 2011: Exposure to potential CYP450 pharmacokinetic drugâ€“drug interactions. Pain Practice, 2012, 12, 81-82.	1.9	1
66	CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. British Journal of Clinical Pharmacology, 2012, 73, 257-267.	2.4	39
67	Gender, but not CYP7A1 or SLCO1B1 Polymorphism, Affects the Fasting Plasma Concentrations of Bile Acids in Human Beings. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 245-252.	2.5	37
68	Towards Safer and More Predictable Drug Treatment â€“ Reflections from Studies of the First <scp>BCPT</scp> Prize Awardee. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 207-218.	2.5	9
69	No Antidotal Effect of Intravenous Lipid Emulsion in Experimental Amitriptyline Intoxication Despite Significant Entrapment of Amitriptyline. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 378-383.	2.5	27
70	Intravenous Oxycodone for Pain Relief in the First Stage of Labour â€“ Maternal Pharmacokinetics and Neonatal Exposure. Basic and Clinical Pharmacology and Toxicology, 2012, 111, 182-188.	2.5	23
71	Rifampicin has a Profound Effect on the Pharmacokinetics of Oral Sâ€Ketamine and Less on Intravenous Sâ€Ketamine. Basic and Clinical Pharmacology and Toxicology, 2012, 111, 325-332.	2.5	42
72	The Analgesic Concentration of Oxycodone with Coâ€administration of Paracetamol â€“ A Doseâ€Finding Study in Adult Patients Undergoing Laparoscopic Cholecystectomy. Basic and Clinical Pharmacology and Toxicology, 2012, 111, 391-395.	2.5	21

#	Article	IF	Citations
73	Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake. Pharmacological Reviews, 2011, 63, 157-181.	16.0	546
74	Pharmacokinetics of Intravenous Paracetamol in Elderly Patients. Clinical Pharmacokinetics, 2011, 50, 121-129.	3.5	63
75	Effect of Inhibition of Cytochrome P450 Enzymes 2D6 and 3A4 on the Pharmacokinetics of Intravenous Oxycodone. Clinical Drug Investigation, 2011, 31, 143-153.	2.2	46
76	Elimination of Intravenous Oxycodone in the Elderly. Drugs and Aging, 2011, 28, 41-50.	2.7	41
77	Itraconazole, a P-Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin-Inhibiting Effect of Aliskiren. Journal of Clinical Pharmacology, 2011, 51, 359-367.	2.0	54
78	The Effect of pH on the In-vitro Dissolution of Three Second-generation Sulphonylurea Preparations: Mechanism of Antacid-sulphonylurea Interaction. Journal of Pharmacy and Pharmacology, 2011, 48, 899-901.	2.4	6
79	Inhibition of Cytochrome P450 3A by Clarithromycin Uniformly Affects the Pharmacokinetics and Pharmacodynamics of Oxycodone in Young and Elderly Volunteers. Journal of Clinical Psychopharmacology, 2011, 31, 302-308.	1.4	33
80	Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. British Journal of Clinical Pharmacology, 2011, 71, 718-726.	2.4	80
81	Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans. Clinical Pharmacology and Therapeutics, 2011, 89, 579-586.	4.7	50
82	The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast. European Journal of Clinical Pharmacology, 2011, 67, 151-155.	1.9	12
83	Interaction of oxycodone and voriconazoleâ€"a case series of patients with cancer pain supports the findings of randomised controlled studies with healthy subjects. European Journal of Clinical Pharmacology, 2011, 67, 863-864.	1.9	13
84	No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid. European Journal of Clinical Pharmacology, 2011, 67, 1159-1167.	1.9	6
85	Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses. Drug Metabolism and Disposition, 2011, 39, 1977-1986.	3.3	58
86	Donor Simvastatin Treatment Abolishes Rat Cardiac Allograft Ischemia/Reperfusion Injury and Chronic Rejection Through Microvascular Protection. Circulation, 2011, 124, 1138-1150.	1.6	69
87	Reevaluation of the Microsomal Metabolism of Montelukast: Major Contribution by CYP2C8 at Clinically Relevant Concentrations. Drug Metabolism and Disposition, 2011, 39, 904-911.	3.3	42
88	Miconazole Oral Gel Increases Exposure to Oral Oxycodone by Inhibition of CYP2D6 and CYP3A4. Antimicrobial Agents and Chemotherapy, 2011, 55, 1063-1067.	3.2	30
89	Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. European Journal of Clinical Pharmacology, 2010, 66, 387-397.	1.9	61
90	Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. European Journal of Clinical Pharmacology, 2010, 66, 497-502.	1.9	24

#	Article	IF	Citations
91	Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren. European Journal of Clinical Pharmacology, 2010, 66, 865-870.	1.9	7
92	Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. European Journal of Clinical Pharmacology, 2010, 66, 977-985.	1.9	58
93	High performance liquid chromatographyâ€“tandem mass spectrometry for the determination of bile acid concentrations in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 51-60.	2.3	90
94	St John's wort greatly reduces the concentrations of oral oxycodone. European Journal of Pain, 2010, 14, 854-859.	2.8	59
95	Intravenous Lipid Emulsion Sequesters Amiodarone in Plasma and Eliminates Its Hypotensive Action in Pigs. Annals of Emergency Medicine, 2010, 56, 402-408.e2.	0.6	80
96	Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral Sâ€ketamine. European Journal of Pain, 2010, 14, 625-629.	2.8	42
97	SLCO1B1 Polymorphism and Oral Antidiabetic Drugs. Basic and Clinical Pharmacology and Toxicology, 2010, 107, 775-781.	2.5	34
98	Grapefruit Juice Enhances the Exposure to Oral Oxycodone. Basic and Clinical Pharmacology and Toxicology, 2010, 107, 782-788.	2.5	48
99	Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. British Journal of Clinical Pharmacology, 2010, 70, 78-87.	2.4	67
100	Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast. Clinical Pharmacology and Therapeutics, 2010, 88, 223-230.	4.7	54
101	Effect of Telithromycin on the Pharmacokinetics and Pharmacodynamics of Oral Oxycodone. Journal of Clinical Pharmacology, 2010, 50, 101-108.	2.0	31
102	Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Current Opinion in Investigational Drugs, 2010, 11, 323-32.	2.3	63
103	Reduced benzodiazepine tolerance, but increased flumazenil-precipitated withdrawal in AMPA-receptor GluR-A subunit-deficient mice. Pharmacology Biochemistry and Behavior, 2009, 92, 283-290.	2.9	12
104	Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib. European Journal of Clinical Pharmacology, 2009, 65, 89-95.	1.9	16
105	Voriconazole drastically increases exposure to oral oxycodone. European Journal of Clinical Pharmacology, 2009, 65, 263-271.	1.9	75
106	No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. British Journal of Clinical Pharmacology, 2009, 68, 207-213.	2.4	52
107	Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics, 2009, 10, 1617-1624.	1.3	171
108	CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe. Drug Metabolism and Disposition, 2009, 37, 2359-2366.	3.3	49

#	Article	IF	Citations
109	Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans. Pharmacogenetics and Genomics, 2009, 19, 447-457.	1.5	56
110	Rifampin Greatly Reduces the Plasma Concentrations of Intravenous and Oral Oxycodone. Anesthesiology, 2009, 110, 1371-1378.	2.5	90
111	Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. European Journal of Clinical Pharmacology, 2008, 64, 17-24.	1.9	42
112	Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. European Journal of Clinical Pharmacology, 2008, 64, 25-30.	1.9	77
113	Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. European Journal of Clinical Pharmacology, 2008, 64, 511-519.	1.9	16
114	Global analysis of genetic variation inÂSLCO1B1. Pharmacogenomics, 2008, 9, 19-33.	1.3	168
115	Effect of Clarithromycin and Itraconazole on the Pharmacokinetics of Ropivacaine. Basic and Clinical Pharmacology and Toxicology, 2008, 88, 187-191.	0.0	0
116	In vitro Inhibition of CYP1A2 by Model Inhibitors, Antiâ€inflammatory Analgesics and Female Sex Steroids: Predictability of in vivo Interactions. Basic and Clinical Pharmacology and Toxicology, 2008, 103, 157-165.	2.5	41
117	The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo. Clinical Pharmacology and Therapeutics, 2008, 84, 403-411.	4.7	79
118	Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism. Clinical Pharmacology and Therapeutics, 2008, 84, 488-496.	4.7	71
119	No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. British Journal of Clinical Pharmacology, 2008, 65, 78-86.	2.4	52
120	Shift of statin use towards the elderly in 1995â"2005: a nationâ€wide register study in Finland. British Journal of Clinical Pharmacology, 2008, 66, 405-410.	2.4	30
121	The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. British Journal of Clinical Pharmacology, 2008, 66, 818-825.	2.4	62
122	Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin. Clinical Pharmacokinetics, 2008, 47, 463-474.	3.5	177
123	Long-term persistence with statin therapy: A nationwide register study in Finland. Clinical Therapeutics, 2008, 30, 2228-2240.	2.5	65
124	Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide. Journal of Clinical Pharmacology, 2008, 48, 311-321.	2.0	83
125	Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics Journal, 2008, 8, 268-277.	2.0	59
126	Trimethoprim and the CYP2C8[*]3 Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone. Drug Metabolism and Disposition, 2008, 36, 73-80.	3.3	110

#	Article	IF	Citations
127	Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenetics and Genomics, 2008, 18, 77-90.	1.5	71
128	Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenetics and Genomics, 2008, 18, 921-926.	1.5	29
129	Determination of Oxycodone, Noroxycodone, Oxymorphone, and Noroxymorphone in Human Plasma by Liquid Chromatography-Electrospray-Tandem Mass Spectrometry. Therapeutic Drug Monitoring, 2008, 30, 333-340.	2.0	40
130	Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenetics and Genomics, 2008, 18, 937-942.	1.5	59
131	Pharmacokinetics of Ropivacaine in Patients with Chronic End-stage Liver Disease. Anesthesiology, 2007, 106, 43-55.	2.5	27
132	Effects of Daily Ingestion of Cranberry Juice on the Pharmacokinetics of Warfarin, Tizanidine, and Midazolamâ€”Probes of CYP2C9, CYP1A2, and CYP3A4. Clinical Pharmacology and Therapeutics, 2007, 81, 833-839.	4.7	84
133	Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. British Journal of Clinical Pharmacology, 2007, 63, 116-120.	2.4	21
134	Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. British Journal of Clinical Pharmacology, 2007, 63, 732-740.	2.4	66
135	Effect of voriconazole on the pharmacokinetics of diclofenac. Fundamental and Clinical Pharmacology, 2007, 21, 651-656.	1.9	23
136	Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen. European Journal of Clinical Pharmacology, 2007, 63, 463-469.	1.9	34
137	Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. European Journal of Clinical Pharmacology, 2007, 63, 829-836.	1.9	13
138	Voriconazole and fluconazole increase the exposure to oral diazepam. European Journal of Clinical Pharmacology, 2007, 63, 941-949.	1.9	43
139	Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenetics and Genomics, 2006, 16, 801-808.	1.5	96
140	SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenetics and Genomics, 2006, 16, 873-879.	1.5	425
141	Differential Inhibition of Cytochrome P450 3A4, 3A5 and 3A7 by Five Human Immunodeficiency Virus (HIV) Protease Inhibitors in vitro. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 79-85.	2.5	100
142	Drug-Related Visits to a District Hospital Emergency Room. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 212-217.	2.5	30
143	Effect of Rifampicin on the Pharmacokinetics of Atenolol. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 555-558.	2.5	16
144	Pioglitazone is Metabolised by CYP2C8 and CYP3A4 in vitro: Potential for Interactions with CYP2C8 Inhibitors. Basic and Clinical Pharmacology and Toxicology, 2006, 99, 44-51.	2.5	123

#	Article	IF	Citations
145	Effect of Fluvoxamine and Erythromycin on the Pharmacokinetics of Oral Lidocaine. Basic and Clinical Pharmacology and Toxicology, 2006, 99, 168-172.	2.5	11
146	Effect of rifampicin on the pharmacokinetics of pioglitazone. British Journal of Clinical Pharmacology, 2006, 61, 70-78.	2.4	75
147	Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. British Journal of Clinical Pharmacology, 2006, 61, 706-715.	2.4	51
148	Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. British Journal of Clinical Pharmacology, 2006, 62, 345-357.	2.4	62
149	Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clinical Pharmacology and Therapeutics, 2006, 79, 231-242.	4.7	44
150	Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clinical Pharmacology and Therapeutics, 2006, 79, 362-370.	4.7	116
151	SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clinical Pharmacology and Therapeutics, 2006, 80, 356-366.	4.7	215
152	Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Clinical Pharmacology and Therapeutics, 2006, 80, 502-508.	4.7	32
153	Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clinical Pharmacology and Therapeutics, 2006, 80, 565-581.	4.7	705
154	Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. European Journal of Clinical Pharmacology, 2006, 62, 217-223.	1.9	32
155	Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. European Journal of Clinical Pharmacology, 2006, 62, 409-415.	1.9	106
156	Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. European Journal of Clinical Pharmacology, 2006, 62, 451-461.	1.9	59
157	Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. European Journal of Clinical Pharmacology, 2006, 62, 463-472.	1.9	79
158	Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. European Journal of Clinical Pharmacology, 2006, 62, 503-509.	1.9	30
159	The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. European Journal of Clinical Pharmacology, 2006, 62, 645-651.	1.9	24
160	Effects of the Antifungals Voriconazole and Fluconazole on the Pharmacokinetics of S -(+)- and R -(â^')-Ibuprofen. Antimicrobial Agents and Chemotherapy, 2006, 50, 1967-1972.	3.2	47
161	Rofecoxib Is a Potent, Metabolism-Dependent Inhibitor of CYP1A2: Implications for in Vitro Prediction of Drug Interactions. Drug Metabolism and Disposition, 2006, 34, 2091-2096.	3.3	37
162	Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenetics and Genomics, 2005, 15, 303-309.	1.5	112

#	Article	IF	Citations
163	Dose-dependent Inhibition of Platelet Function by Acetaminophen in Healthy Volunteers. Anesthesiology, 2005, 103, 712-717.	2.5	66
164	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clinical Pharmacology and Therapeutics, 2005, 77, 404-414.	4.7	99
165	Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clinical Pharmacology and Therapeutics, 2005, 77, 468-478.	4.7	320
166	Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clinical Pharmacology and Therapeutics, 2005, 78, 154-167.	4.7	132
167	Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clinical Pharmacology and Therapeutics, 2005, 78, 400-411.	4.7	87
168	Cyclosporine markedly raises the plasma concentrations of repaglinide. Clinical Pharmacology and Therapeutics, 2005, 78, 388-399.	4.7	180
169	Out-of-hospital administration of activated charcoal by emergency medical services. Annals of Emergency Medicine, 2005, 45, 207-212.	0.6	32
170	Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. British Journal of Clinical Pharmacology, 2005, 59, 433-439.	2.4	40
171	Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. British Journal of Clinical Pharmacology, 2005, 60, 208-217.	2.4	36
172	Effects of grapefruit juice on the absorption of levothyroxine. British Journal of Clinical Pharmacology, 2005, 60, 337-341.	2.4	56
173	Effects of grapefruit juice on the pharmacokinetics of acebutolol. British Journal of Clinical Pharmacology, 2005, 60, 659-663.	2.4	38
174	Comparison of 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors (Statins) as Inhibitors of Cytochrome P450 2C8. Basic and Clinical Pharmacology and Toxicology, 2005, 97, 104-108.	2.5	34
175	Metabolism of Repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of Fibrates and Rifampicin. Basic and Clinical Pharmacology and Toxicology, 2005, 97, 249-256.	2.5	149
176	Effect of Itraconazole on the Pharmacokinetics of Atenolol. Basic and Clinical Pharmacology and Toxicology, 2005, 97, 395-398.	2.5	11
177	The Effect of Erythromycin and Fluvoxamine on the Pharmacokinetics of Intravenous Lidocaine. Anesthesia and Analgesia, 2005, 100, 1352-1356.	2.2	32
178	Risks Associated With Selective Serotonin Reuptake Inhibitors in Pregnancy. Obstetrics and Gynecology, 2005, 106, 1289-1296.	2.4	180
179	Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. British Journal of Clinical Pharmacology, 2004, 58, 56-60.	2.4	142
180	Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. British Journal of Clinical Pharmacology, 2004, 58, 390-396.	2.4	35

#	Article	IF	Citations
181	Effect of Itraconazole on the Pharmacokinetics of Inhaled Lidocaine. Basic and Clinical Pharmacology and Toxicology, 2004, 95, 120-123.	0.0	12
182	The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. British Journal of Clinical Pharmacology, 2004, 57, 441-447.	2.4	81
183	Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro. British Journal of Clinical Pharmacology, 2004, 57, 349-353.	2.4	84
184	Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clinical Pharmacology and Therapeutics, 2004, 75, 101-109.	4.7	81
185	Orange juice substantially reduces the bioavailability of the Î²-adrenergicâ€“blocking agent celiprolol. Clinical Pharmacology and Therapeutics, 2004, 75, 184-190.	4.7	92
186	Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction*1. Clinical Pharmacology and Therapeutics, 2004, 75, 331-341.	4.7	98
187	Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clinical Pharmacology and Therapeutics, 2004, 76, 239-249.	4.7	80
188	Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2?mediated presystemic metabolism. Clinical Pharmacology and Therapeutics, 2004, 76, 598-606.	4.7	130
189	Prescription of Hazardous Drugs During Pregnancy. Drug Safety, 2004, 27, 899-908.	3.2	50
190	High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics and Genomics, 2004, 14, 429-440.	5.7	391
191	Effect of Caffeineâ€Containing versus Decaffeinated Coffee on Serum Clozapine Concentrations in Hospitalised Patients. Basic and Clinical Pharmacology and Toxicology, 2004, 94, 13-18.	2.5	22
192	Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clinical Pharmacology and Therapeutics, 2003, 73, 192-198.	4.7	126
193	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia, 2003, 46, 347-351.	6.3	269
194	Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia, 2003, 46, 1319-1323.	6.3	167
195	Effect of ciprofloxacin on the pharmacokinetics of ropivacaine. European Journal of Clinical Pharmacology, 2003, 58, 653-657.	1.9	25
196	Prescription drugs during pregnancy and lactationâ€”a Finnish register-based study. European Journal of Clinical Pharmacology, 2003, 59, 127-133.	1.9	74
197	Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clinical Pharmacology and Therapeutics, 2003, 73, 538-544.	4.7	170
198	Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide. Clinical Pharmacology and Therapeutics, 2003, 74, 25-31.	4.7	20

#	Article	IF	Citations
199	Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. Clinical Pharmacology and Therapeutics, 2003, 74, 178-185.	4.7	33
200	Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clinical Pharmacology and Therapeutics, 2003, 74, 380-387.	4.7	154
201	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects. British Journal of Clinical Pharmacology, 2003, 56, 427-432.	2.4	40
202	Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. British Journal of Clinical Pharmacology, 2003, 57, 181-187.	2.4	66
203	Pharmacokinetic Interactions with Rifampicin. Clinical Pharmacokinetics, 2003, 42, 819-850.	3.5	591
204	Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes. Drug Metabolism and Disposition, 2002, 30, 1352-1356.	3.3	174
205	Effect of Albumin and Cytosol on Enzyme Kinetics of Tolbutamide Hydroxylation and on Inhibition of CYP2C9 by Gemfibrozil in Human Liver Microsomes. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 43-49.	2.5	19
206	Trimethoprim and Sulfamethoxazole are Selective Inhibitors of CYP2C8 and CYP2C9, Respectively. Drug Metabolism and Disposition, 2002, 30, 631-635.	3.3	141
207	Isoniazid is a mechanism-based inhibitor of cytochrome P 450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. European Journal of Clinical Pharmacology, 2002, 57, 799-804.	1.9	143
208	Cancer incidence among patients using antiepileptic drugs: a long-term follow-up of 28,000 patients. European Journal of Clinical Pharmacology, 2002, 58, 137-141.	1.9	56
209	Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. Clinical Pharmacology and Therapeutics, 2002, 72, 362-369.	4.7	62
210	Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes*. Clinical Pharmacology and Therapeutics, 2002, 72, 326-332.	4.7	172
211	Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clinical Pharmacology and Therapeutics, 2002, 72, 685-691.	4.7	296
212	Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. European Journal of Clinical Pharmacology, 2001, 57, 37-42.	1.9	37
213	Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. British Journal of Clinical Pharmacology, 2001, 52, 399-407.	2.4	18
214	In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). British Journal of Clinical Pharmacology, 2001, 52, 547-553.	2.4	131
215	Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine. Clinical Pharmacology and Therapeutics, 2001, 70, 344-350.	4.7	23
216	Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clinical Pharmacology and Therapeutics, 2001, 70, 484-492.	4.7	18

#	Article	IF	Citations
217	Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clinical Pharmacology and Therapeutics, 2001, 69, 194-200.	4.7	59
218	Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clinical Pharmacology and Therapeutics, 2001, 69, 340-345.	4.7	174
219	Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clinical Pharmacology and Therapeutics, 2001, 69, 400-406.	4.7	104
220	The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clinical Pharmacology and Therapeutics, 2001, 70, 58-65.	4.7	88
221	Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs. Clinical Pharmacology and Therapeutics, 2001, 70, 255-260.	4.7	25
222	Effect of Clarithromycin and Itraconazole on the Pharmacokinetics of Ropivacaine. Basic and Clinical Pharmacology and Toxicology, 2001, 88, 187-191.	0.0	24
223	The Effect of Erythromycin, Fluvoxamine, and Their Combination on the Pharmacokinetics of Ropivacaine. Anesthesia and Analgesia, 2000, 91, 1207-1212.	2.2	13
224	Identification of Drugs Ingested in Acute Poisoning: Correlation of Patient History With Drug Analyses. Therapeutic Drug Monitoring, 2000, 22, 749-752.	2.0	49
225	The Effect of Erythromycin, Fluvoxamine, and Their Combination on the Pharmacokinetics of Ropivacaine. Anesthesia and Analgesia, 2000, 91, 1207-1212.	2.2	18
226	Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1â€²â€hydroxylation. British Journal of Clinical Pharmacology, 2000, 50, 333-337.	2.4	65
227	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. British Journal of Clinical Pharmacology, 2000, 50, 591-595.	2.4	46
228	The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 770-775.	2.3	133
229	Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. Clinical Pharmacology and Therapeutics, 2000, 67, 215-221.	4.7	45
230	Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation. Clinical Pharmacology and Therapeutics, 2000, 67, 382-390.	4.7	42
231	Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clinical Pharmacology and Therapeutics, 2000, 68, 122-129.	4.7	235
232	Morphine clearance and effects in newborn infants in relation to gestational age. Clinical Pharmacology and Therapeutics, 2000, 68, 160-166.	4.7	60
233	Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clinical Pharmacology and Therapeutics, 2000, 68, 384-390.	4.7	154
234	The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clinical Pharmacology and Therapeutics, 2000, 68, 487-494.	4.7	105

#	Article	IF	Citations
235	Rifampin decreases the plasma concentrations and effects of repaglinide. Clinical Pharmacology and Therapeutics, 2000, 68, 495-500.	4.7	91
236	Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clinical Pharmacology and Therapeutics, 2000, 68, 592-597.	4.7	132
237	Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. European Journal of Clinical Pharmacology, 2000, 56, 225-229.	1.9	111
238	Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life. European Journal of Clinical Pharmacology, 2000, 56, 411-415.	1.9	85
239	Gestational age and birth weight effects on plasma clearance of fentanyl in newborn infants. Journal of Pediatrics, 2000, 136, 767-770.	1.8	87
240	Midazolam Î±â€Hydroxylation by Human Liver Microsomes in vitro: Inhibition by Calcium Channel Blockers, Itraconazole and Ketoconazole. Basic and Clinical Pharmacology and Toxicology, 1999, 85, 157-161.	0.0	56
241	Interactions of Buspirone with Itraconazole and Rifampicin: Effects on the Pharmacokinetics of the Active 1â€(2â€Pyrhnidinyl)â€piperazine Metabolite of Buspirone. Basic and Clinical Pharmacology and Toxicology, 1999, 84, 94-97.	0.0	33
242	Effect of Erythromycin and Itraconazole on the Pharmacokinetics of Oral Lignocaine. Basic and Clinical Pharmacology and Toxicology, 1999, 84, 143-146.	0.0	31
243	Lack of Effect of Terfenadine on the Pharmacokinetics of the CYP3A4 Substrate Buspirone. Basic and Clinical Pharmacology and Toxicology, 1999, 84, 165-169.	0.0	9
244	Fluvoxamine is a More Potent Inhibitor of Lidocaine Metabolism than Ketoconazole and Erythromycin in vitro. Basic and Clinical Pharmacology and Toxicology, 1999, 85, 201-205.	0.0	32
245	Itraconazole Decreases the Clearance and Enhances the Effects of Intravenously Administered Methylprednisolone in Healthy Volunteers. Basic and Clinical Pharmacology and Toxicology, 1999, 85, 29-32.	0.0	53
246	Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clinical Pharmacology and Therapeutics, 1999, 66, 448-453.	4.7	59
247	Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clinical Pharmacology and Therapeutics, 1999, 66, 33-39.	4.7	103
248	The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clinical Pharmacology and Therapeutics, 1999, 65, 377-381.	4.7	36
249	Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clinical Pharmacology and Therapeutics, 1999, 66, 118-127.	4.7	175
250	Cytochrome P450?inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clinical Pharmacology and Therapeutics, 1999, 66, 589-593.	4.7	50
251	Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam*1. Clinical Pharmacology and Therapeutics, 1999, 66, 401-407.	4.7	33
252	Determination of Buspirone and 1-(2-pyrimidinyl)-piperazine (1-PP) in Human Plasma by Capillary Gas Chromatography. Therapeutic Drug Monitoring, 1999, 21, 317.	2.0	7

#	Article	IF	Citations
253	Plasma Clearance of Fentanyl in Relation To Gestational Age and Birth Weight. Pediatric Research, 1999, 45, 901-901.	2.3	0
254	Effect of itraconazole on the pharmacokinetics of atorvastatin*. Clinical Pharmacology and Therapeutics, 1998, 64, 58-65.	4.7	267
255	Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid*. Clinical Pharmacology and Therapeutics, 1998, 63, 397-402.	4.7	250
256	Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin*. Clinical Pharmacology and Therapeutics, 1998, 64, 648-654.	4.7	42
257	Grapefruit juice substantially increases plasma concentrations of buspirone*. Clinical Pharmacology and Therapeutics, 1998, 64, 655-660.	4.7	119
258	Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole*. Clinical Pharmacology and Therapeutics, 1998, 64, 363-368.	4.7	103
259	Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone*. Clinical Pharmacology and Therapeutics, 1998, 63, 640-645.	4.7	64
260	Grapefruit juiceâ€"simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors*. Clinical Pharmacology and Therapeutics, 1998, 64, 477-483.	4.7	283
261	Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations*. Clinical Pharmacology and Therapeutics, 1998, 64, 177-182.	4.7	267
262	Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole*. Clinical Pharmacology and Therapeutics, 1998, 63, 332-341.	4.7	389
263	The Effect of Dexamethasone on the Pharmacokinetics of Triazolam. Basic and Clinical Pharmacology and Toxicology, 1998, 83, 135-138.	0.0	37
264	The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. European Journal of Clinical Pharmacology, 1998, 54, 53-58.	1.9	246
265	A prospective study of acute poisonings in Finnish hospital patients. Human and Experimental Toxicology, 1998, 17, 307-311.	2.2	34
266	The Effect of Intravenous and Oral Fluconazole on the Pharmacokinetics and Pharmacodynamics of Intravenous Alfentanil. Anesthesia and Analgesia, 1998, 87, 190-194.	2.2	32
267	The Effect of Intravenous and Oral Fluconazole on the Pharmacokinetics and Pharmacodynamics of Intravenous Alfentanil. Anesthesia and Analgesia, 1998, 87, 190-194.	2.2	45
268	Methylprednisolone Exposure, Rather than Dose, Predicts Adrenal Suppression and Growth Inhibition in Children with Liver and Renal Transplants1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 75-77.	3.6	30
269	Pharmacokinetics of verapamil in overdose. Human and Experimental Toxicology, 1997, 16, 35-37.	2.2	21
270	Effect of Delayed Administration of Activated Charcoal on the Absorption of Conventional and Slow-Release Verapamil. Journal of Toxicology: Clinical Toxicology, 1997, 35, 263-268.	1.5	28

#	Article	IF	Citations
271	Prevention of amlodipine absorption by activated charcoal: effect of delay in charcoal administration. British Journal of Clinical Pharmacology, 1997, 43, 29-33.	2.4	11
272	Effect of Time Interval between Food and Drug Ingestion on the Absorption of Oxybutynin from a Controlledâ€Release Tablet. Basic and Clinical Pharmacology and Toxicology, 1997, 81, 31-34.	0.0	15
273	Cigarette smoking does not affect thiopentone pharmacodynamic or pharmacokinetic behaviour. Canadian Journal of Anaesthesia, 1997, 44, 1269-1274.	1.6	5
274	Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole*. Clinical Pharmacology and Therapeutics, 1997, 62, 348-354.	4.7	147
275	Itraconazole increases plasma concentrations of quinidine*. Clinical Pharmacology and Therapeutics, 1997, 62, 510-517.	4.7	92
276	Rifampin reduces plasma concentrations and effects of zolpidem*. Clinical Pharmacology and Therapeutics, 1997, 62, 629-634.	4.7	62
277	Triazolam is ineffective in patients taking rifampin. Clinical Pharmacology and Therapeutics, 1997, 61, 8-14.	4.7	96
278	Itraconazole greatly increases plasma concentrations and effects of felodipine. Clinical Pharmacology and Therapeutics, 1997, 61, 410-415.	4.7	132
279	Effect of Activated Charcoal on the Pharmacokinetics of Pholcodine, with Special Reference to Delayed Charcoal Ingestion. Therapeutic Drug Monitoring, 1997, 19, 46-50.	2.0	12
280	Itraconazole Decreases Renal Clearance of Digoxin. Therapeutic Drug Monitoring, 1997, 19, 609-613.	2.0	169
281	Prevention of amlodipine absorption by activated charcoal: effect of delay in charcoal administration. British Journal of Clinical Pharmacology, 1997, 43, 29-33.	2.4	22
282	Effect of Diltiazem on Midazolam and Alfentanil Disposition in Patients Undergoing Coronary Artery Bypass Grafting. Anesthesiology, 1996, 85, 1246-1252..	2.5	68
283	The Effect of the Systemic Antimycotics, Itraconazole and Fluconazole, on the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Midazolam. Anesthesia and Analgesia, 1996, 82, 511-516.	2.2	124
284	The Effect of the Systemic Antimycotics, Itraconazole and Fluconazole, on the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Midazolam. Anesthesia and Analgesia, 1996, 82, 511-516.	2.2	187
285	Interaction between Erythromycin and the Benzodiazepines Diazepam and Flunitrazepam. Basic and Clinical Pharmacology and Toxicology, 1996, 78, 117-122.	0.0	22
286	The Effect of Activated Charcoal on the Absorption of Fluoxetine, with Special Reference to Delayed Charcoal Administration. Basic and Clinical Pharmacology and Toxicology, 1996, 79, 270-273.	0.0	15
287	Itraconazole Increases Serum Digoxin Concentration. Basic and Clinical Pharmacology and Toxicology, 1996, 79, 274-276.	0.0	49
288	Concentrations and Effects of Oral Midazolam are Greatly Reduced in Patients Treated with Carbamazepine or Phenytoin. Epilepsia, 1996, 37, 253-257.	5.1	133

#	Article	IF	Citations
289	Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clinical Pharmacology and Therapeutics, 1996, 59, 7-13.	4.7	219
290	The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clinical Pharmacology and Therapeutics, 1996, 60, 326-331.	4.7	52
291	Diltiazem enhances the effects of triazolam by inhibiting its metabolism*. Clinical Pharmacology and Therapeutics, 1996, 59, 369-375.	4.7	72
292	Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clinical Pharmacology and Therapeutics, 1996, 60, 54-61.	4.7	254
293	Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. British Journal of Clinical Pharmacology, 1996, 41, 319-323.	2.4	60
294	Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. British Journal of Clinical Pharmacology, 1996, 42, 465-470.	2.4	58
295	Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. British Journal of Clinical Pharmacology, 1996, 42, 465-470.	2.4	38
296	Lack of Effect of Antimycotic Itraconazole on the Pharmacokinetics or Pharmacodynamics of Temazepam. Therapeutic Drug Monitoring, 1996, 18, 124-127.	2.0	25
297	Interaction between Erythromycin and Nitrazepam in Healthy Volunteers. Basic and Clinical Pharmacology and Toxicology, 1995, 76, 255-258.	0.0	10
298	Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clinical Pharmacology and Therapeutics, 1995, 58, 127-131.	4.7	138
299	Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. British Journal of Clinical Pharmacology, 1995, 40, 270-272.	2.4	84
300	Itraconazole interacts with felodipine. Journal of the American Academy of Dermatology, 1995, 33, 134-135.	1.2	45
301	The Effect of Activated Charcoal on the Absorption and Elimination of Astemizole. Human and Experimental Toxicology, 1994, 13, 502-505.	2.2	12
302	Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology and Therapeutics, 1994, 56, 601-607.	4.7	287
303	Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology and Therapeutics, 1994, 55, 481-485.	4.7	386
304	Enhancement of Drug Absorption by Antacids. Clinical Pharmacokinetics, 1994, 27, 120-128.	3.5	41
305	Dose of midazolam should be reduced during diltiazem and verapamil treatments.. British Journal of Clinical Pharmacology, 1994, 37, 221-225.	2.4	164
306	Inhibition of Terfenadine Metabolism. Clinical Pharmacokinetics, 1994, 27, 1-5.	3.5	74

#	Article	IF	Citations
307	Lack of Interaction of Erythromycin with Temazepam. Therapeutic Drug Monitoring, 1994, 16, 548-551.	2.0	16
308	A potentially hazardous interaction between erythromycin and midazolam. Clinical Pharmacology and Therapeutics, 1993, 53, 298-305.	4.7	313
309	Failure of Oral Activated Charcoal to Accelerate the Elimination of Amiodarone and Chloroquine. Human and Experimental Toxicology, 1992, 11, 491-494.	2.2	8
310	Reversible Adsorption of Nicotinic Acid onto Charcoal In Vitro. Journal of Pharmaceutical Sciences, 1992, 81, 917-919.	3.3	11
311	Enhancement of absorption and effect of glipizide by magnesium hydroxide. Clinical Pharmacology and Therapeutics, 1991, 49, 39-43.	4.7	16
312	Interference of dairy products with the absorption of ciprofloxacin. Clinical Pharmacology and Therapeutics, 1991, 50, 498-502.	4.7	110
313	Effect of Activated Charcoal on the Absorption of Amiodarone. Human and Experimental Toxicology, 1991, 10, 327-329.	2.2	15
314	Therapeutic Cyclosporine Monitoring. Therapeutic Drug Monitoring, 1990, 12, 353-358.	2.0	4
315	The clinical significance of foodâ€drug interactions: a review. Medical Journal of Australia, 1989, 150, 36-40.	1.7	32
316	Oral Activated Charcoal in the Treatment of Intoxications. Medical Toxicology, 1988, 3, 33-58.	1.7	151
317	Can barbiturate anaesthesia cure infantile spasms?. Brain and Development, 1988, 10, 300-304.	1.1	2
318	Effect of Total Drug Concentration on the Free Fraction in Uremic Sera. Therapeutic Drug Monitoring, 1986, 8, 27-31.	2.0	8
319	Bumetanide kinetics in renal failure. Clinical Pharmacology and Therapeutics, 1985, 37, 582-588.	4.7	21
320	Activated Charcoal and Syrup of Ipecac in Prevention of Cimetidine and Pindolol Absorption in man after Administration of Metoclopramide as an Antiemetic Agent. Journal of Toxicology: Clinical Toxicology, 1984, 22, 103-114.	1.5	36
321	Adsorption of Sulfonylureas onto Activated Charcoal In Vitro. Journal of Pharmaceutical Sciences, 1984, 73, 253-256.	3.3	28
322	Tolfenamic Acid, Metoclopramide, Caffeine and Their Combinations in The Treatment of Migraine Attacks. Cephalalgia, 1984, 4, 253-263.	3.9	57
323	Effect of Ethanol and pH on the Adsorption of Drugs to Activated Charcoal: Studies in Vitro and in Man. Acta Pharmacologica Et Toxicologica, 1984, 54, 1-7.	0.0	45
324	Effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics. Clinical Pharmacology and Therapeutics, 1983, 33, 386-393.	4.7	62

#	Article	IF	Citations
325	Pharmacokinetics of antiepileptic drugs. Acta Neurologica Scandinavica, 1983, 68, 17-27.	2.1	17
326	Capacity of Two Forms of Activated Charcoal to Adsorb Nefopam In Vitro and to Reduce its Toxicity In Vivo. Journal of Toxicology: Clinical Toxicology, 1983, 21, 333-342.	1.5	14
327	Clinical Pharmacokinetics of Oral Activated Charcoal in Acute Intoxications. Clinical Pharmacokinetics, 1982, 7, 465-489.	3.5	159
328	Human metabolism of tolfenamic acid. II. Structure of metabolites and C-13 NMR assignments of fenamates. European Journal of Drug Metabolism and Pharmacokinetics, 1982, 7, 269-276.	1.6	13
329	Effect of Phenytoin on Serum Lipoproteins in Middle-Aged Men. Journal of Cardiovascular Pharmacology, 1981, 3, 207-214.	1.9	8
330	Pharmacokinetics of intravenously administered bumetanide in man. Journal of Pharmacokinetics and Pharmacodynamics, 1980, 8, 219-228.	0.6	29
331	Acute Dapsone Intoxication: A Case with Prolonged Symptoms. Clinical Toxicology, 1979, 14, 79-85.	0.5	35
332	Severe Poisoning in a Child Caused by a Small Dose of Clonidine. Clinical Toxicology, 1979, 14, 369-374.	0.5	16
333	Bioavailability of Phenytoin. Clinical Pharmacokinetics, 1979, 4, 91-103.	3.5	59
334	Sotalol Intoxication, Two Patients with Concentration â€•Effect Relationships. Acta Pharmacologica Et Toxicologica, 1979, 45, 52-57.	0.0	22